Moderna, Seqirus and more—News of Note by Angus Liu Wednesday, February 13, 2019 Here is some other vaccine news of note for the week.
Antengene, Otsuka and more—FiercePharmaAsia by Angus Liu Friday, January 4, 2019 Antengene collects $120 million in series B; Otsuka inks new digital-pill pact; MabSpace merges with HJB.
Sanofi flu vaccine cleared in Hong Kong after impurities report by Angus Liu Wednesday, January 2, 2019 As tests by Hong Kong's health department and Sanofi showed no quality problems, Sanofi's Vaxigrip has been cleared for use.
Gardasil-Cervarix, flu vaccines and more—News of Note by Angus Liu Wednesday, December 5, 2018 Here is some other vaccine news of note for the week.
Gene-edited babies, Takeda-Shire and more—FiercePharmaAsia by Angus Liu Friday, November 30, 2018 A Chinese researcher claims is the world's first gene-edited babies; Takeda's Shire deal faces last-minute drama; Celltrion wins first Rituxan biosim nod.
Why China's flu vaccine supply is suffering this season by Angus Liu Wednesday, November 28, 2018 The number of flu shots that passed Chinese regulators so far this season has fallen about 19%, leaving the country short on needed supplies.
Dupixent and vaccines bring Sanofi back to growth by Angus Liu Wednesday, October 31, 2018 Dupixent grew sales by 28% sequentially at constant currencies, to €225 million, and that doesn't even count a recent major approval in asthma.
Officials deny shortage of Seqirus' Fluad in the U.K. by Eric Sagonowsky Wednesday, October 17, 2018 Seqirus says it is phasing delivery of its flu vaccine Fluad to the U.K. ahead of the peak season, though pharmacists have reported a lack of supply.
Sanofi teams with ALA on flu-shot message to U.S. seniors by Eric Sagonowsky Monday, October 15, 2018 As Sanofi mobilizes millions of flu shots, it's working with the American Lung Association to make sure vaccines get to the people who need them.
FluGen’s broadly protective flu vaccine clears phase 1 by Angus Liu Tuesday, October 9, 2018 Through an ongoing "challenge" study, FluGen hopes to see whether the nasal vaccine can fight off the flu virus that doesn't match its own.